Oblenio Bio is a clinical-stage biotechnology company developing tri-specific antibody immunotherapies for refractory autoimmune diseases. Its lead candidate, LBL-051, is a tri-specific T-cell engager targeting BCMA, CD19, and CD3 to deplete B-cells and pursue long-term, drug-free remission and immune reset for patients. - View it on GitHub